Trial Profile
A dose-escalation phase I study of NT-503 in patients with treatment naive wet age-related macular degeneration (AMD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2014
Price :
$35
*
At a glance
- Drugs NT 503 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Neurotech USA
- 15 Sep 2014 Results published on Neurotech company website.
- 15 Sep 2014 New trial record